[Cutaneous leishmaniasis in rheumatoid arthritis].
BACKGROUND
Cutaneous leishmaniasis is a protozoal infection. Its prevalence is increasing, especially in immunocompromised subjects.


METHODS
We report four patients with rheumatoid arthritis, treated with methotrexate and prednisone who developed cutaneous leishmaniasis. Clinical outcome was favorable after institution of antimony therapy in three cases despite the continuation of methotrexate and prednisone. One patient failed to respond to therapy.


CONCLUSIONS
The frequency of cutaneous leishmaniasis is increasing especially in immunocompromised subjects. In our patients, rheumatoid arthritis, corticosteroid therapy and methotrexate were predisposing factors of cutaneous leishmaniasis.
Hachicha
I
I
Service de rhumatologie, CHU Hédi Chaker, 3029 Sfax, Tunisia. mainouhachicha@yahoo.fr
Sellami
M
M
Fourati
H
H
Akrout
R
R
Hdiji
N
N
Baklouti
S
S
D000328:Adult; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016773:Leishmaniasis, Cutaneous / Q000175:diagnosis* / Q000188:drug therapy; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D011241:Prednisone; D008727:Methotrexate